Mitralign, Inc. is the valve repair company with the only direct transcatheter annuloplasty system designed to treat both functional tricuspid regurgitation and mitral regurgitation. We are a venture-backed, medical innovation company located near Boston, Massachusetts, USA.We've developed an innovative therapy for the reduction of functional mitral regurgitation (FMR), a life-threatening cardiac condition affecting four million people in the U.S. alone. The Mitralign Percutaneous Annuloplasty System, MPAS, is intended for the treatment of symptomatic functional mitral regurgitation (MR ≥ 3+) for annular reduction through tissue plication. In addition, we have developed an approach to treating tricuspid valve regurgitation with a delivery system designed for transcatheter tricuspid valve repair. Our unique system provides a new solution for interventional cardiologists and their patients.For the millions of patients who've exhausted other therapeutic options, Mitralign is a lifeline.CAUTION: The Trialign System is an investigational device and is limited by Federal (or United States) Law to investigational use only. It is not available for sale or commercial distribution. The MPAS is not commercially available in the U.S.